Arca
Skip to content
Tools
Tools

RHD: Blood group Rh(D) polypeptide

May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane.

  • Drugs that act on it: 4
  • Approved: 0
  • In phases 1 to 3: 4
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on RHD, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 3
  • Other 1

Approved0

    Phase 30

      Phase 24

      • Atorolimumab
      • Morolimumab
      • Roledumab
      • Rozrolimupab

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        • Symphogen A/S125%

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Blood group Rh(D) polypeptide inhibitor; the rest name their own mechanism.
        AtorolimumabPhase 2—AntibodyOtherBlood group Rh(D) polypeptide other0
        MorolimumabPhase 2—AntibodyInhibitor0
        RoledumabPhase 2—AntibodyInhibitor0
        RozrolimupabPhase 2Symphogen A/SOtherInhibitor0

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Rh deficiency syndrome0.39
        • Blood group antigen abnormality0.18
        • Pregnancy induced alloimmunization0.14
        • Hemolytic disease of fetus and newborn, RH-induced0.12
        • Neoplasm0.10
        • Metabolic disease0.10
        • Alloimmunization0.09
        • Autoimmune thrombocytopenic purpura0.08
        • Gluthathione peroxidase deficiency0.06

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712996, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q02161, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.